TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors. This study is looking at several other research questions, including: 1. Side effects that may be experienced by taking REGN5678 alone or in combination with cemiplimab 2. How REGN5678 alone or in combination with cemiplimab works in the body 3. How much REGN5678 and/or cemiplimab are present in the blood 4. To see if REGN5678 alone or in combination with cemiplimab works to reduce the size of the tumor by helping the immune system destroy the tumor

Sponsor: Regeneron Pharmaceuticals

Where it's recruiting

Arizona

Gilbert · Phoenix · Tucson

California

Santa Monica

Colorado

Denver

Connecticut

New Haven

Florida

Jacksonville · Tampa

Michigan

Detroit

Minnesota

Rochester

New York

New York · Rochester

Ohio

Columbus

Oregon

Portland

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT03972657 · last updated 2026-11-04

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it W · TrialPath